Connect
MJA
MJA

Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?

Ken J Harvey, Richard O Day, William G Campbell and Wendy Lipworth
Med J Aust 2011; 194 (11): 567-568.
Published online: 6 June 2011

The cost differential between these two drugs is no longer defensible

Federal Health Minister Nicola Roxon recently met with an alliance of consumer, industry and other stakeholders to justify the government’s plan to indefinitely delay the listing of seven new medicines on the Pharmaceutical Benefits Scheme (PBS). She argued that, after considering the advice of the Pharmaceutical Benefits Advisory Committee (PBAC), it was the government’s responsibility to decide whether or not to list a new drug, taking into account other priorities across the health portfolio and current fiscal circumstances.1

  • Ken J Harvey1
  • Richard O Day2
  • William G Campbell3
  • Wendy Lipworth4

  • 1 School of Public Health, La Trobe University, Melbourne, VIC.
  • 2 St Vincent’s Hospital and University of New South Wales, Sydney, NSW.
  • 3 Royal Victorian Eye and Ear Hospital, Melbourne, VIC.
  • 4 Australian Institute of Health Innovation, University of New South Wales, Sydney, NSW.

Correspondence: ken.harvey@latrobe.edu.au

Competing interests:

Ken Harvey represented the Chronic Illness Alliance at the Consumers Health Forum PBS Summit. Richard Day is a member of the Ad Hoc Advisory Committee on Drugs in Development for Novartis Australia.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.